Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

Gan & Lee Pharmaceuticals announced positive results from Phase 2 clinical trials for its investigational drugs bofanglutide and GZR4 in patients with type 2 diabetes mellitus (T2DM); bofanglutide showed significant HbA1c and body weight reductions, outperforming semaglutide (Ozempic) in one trial, while GZR4 demonstrated comparable efficacy and safety to insulin degludec (Tresiba), with superior HbA1c reduction in patients previously on basal insulin therapy, however, neither drug has been approved in any country.

Analysis

Gan & Lee Pharmaceuticals has reported highly positive Phase 2 clinical trial data for two investigational type 2 diabetes mellitus (T2DM) treatments, significantly strengthening its development pipeline. Its GLP-1 receptor agonist, bofanglutide, demonstrated superiority over the market leader semaglutide (Ozempic) in a Phase 2b trial, with specific dosing regimens achieving statistically significant (p<0.001) greater reductions in HbA1c; for example, the 18mg bi-weekly dose lowered HbA1c by 2.28% compared to 1.60% for semaglutide. Bofanglutide also led to more substantial weight loss, with reductions ranging from 4.26 kg to 6.54 kg, versus 3.25 kg for the semaglutide group. The company's second candidate, a once-weekly insulin injection GZR4, showed comparable efficacy to once-daily insulin degludec (Tresiba) in one patient group and superior efficacy in patients with prior basal insulin use, reducing HbA1c by 1.26% versus 0.87% for Tresiba (p<0.01). A key potential advantage for GZR4 is that it achieved this control with a 40-50% lower total weekly insulin dosage. As Gan & Lee advances both assets into large-scale Phase 3 programs, these results position the company as a credible future competitor in the lucrative long-acting antidiabetic market.

Key Decisions for Investors

• The superior efficacy and weight loss data of bofanglutide against market leader semaglutide represents a significant de-risking event for Gan & Lee's pipeline and a potential major value driver, contingent on successful Phase 3 outcomes.
• Investors should closely monitor the company's execution of its large-scale Phase 3 trials, as replicating these positive results is the primary hurdle remaining before potential regulatory submission and commercialization.
• While the Phase 2 results are compelling, it is crucial to factor in the inherent risks of late-stage clinical development, including the possibility of trial failure or delays, and the intense competition within the diabetes and weight-loss drug market.